Roche’s Avastin: censored data means ‘no evidence to justify cost’ says NICE
This article was originally published in Scrip
Executive Summary
NICE, the health technology appraisal institute for England and Wales, has issued draft guidance declining to recommend Roche's Avastin (bevacizumab) for advanced ovarian cancer, claiming it would not be cost-effective. In addition, the institute also declined to make any recommendations on the use of Avastin in a lower, unlicensed 7.5mg dose.